Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reproxalap in dry eye disease
NCT06424444Phase 3Completed
- Sponsor
- Aldeyra Therapeutics
- Start
- Apr 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dry eye disease (DED) comparing Reproxalap Ophthalmic Solution (0.25%) with Vehicle Ophthalmic Solution (2 arms). Primary endpoint: Subject-reported Ocular Discomfort at 6 weeks. Started Apr 2024; status: completed.
02
Drugs
reproxalap
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT06424444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06424444.